AACR Pediatric Cancer Progress Report 2025
- 4 February 2026
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (3) , 465-467
Abstract
On December 4, 2025, the American Association for Cancer Research (AACR) released its inaugural AACR Pediatric Cancer Progress Report, which highlights the remarkable scientific and clinical advances transforming outcomes for children (ages 0–14) and adolescents (ages 15–19) with cancer. This first-of-its-kind report encompasses progress against pediatric cancers made over the past decade and chronicles major developments in molecularly targeted therapies, immunotherapies, and genomic profiling that are reshaping pediatric cancer diagnosis, surveillance, and treatment. The report also underscores the enduring challenges that impede progress, including the lack of effective therapies for rarer and aggressive pediatric cancers and the persistent inequities in access to high-quality treatment and supportive care, both in the United States and worldwide. Collectively, these insights reaffirm the urgent need for increased federal investment, strengthened international collaboration, and innovative research strategies to accelerate progress against pediatric cancer. The full report is freely available at PediatricCancerProgressReport.org.Keywords
This publication has 12 references indexed in Scilit:
- Childhood cancer data initiative: expanded access to tumor molecular profiling for children, adolescents, and young adultsJNCI: Journal of the National Cancer Institute, 2025
- Pediatric Cancer Predisposition and Surveillance Update: Summary Perspective and Future DirectionsClinical Cancer Research, 2025
- The Children’s Oncology Group Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult CancersJAMA Oncology, 2025
- Improving quality and quantity of life for childhood cancer survivors globally in the twenty-first centuryNature Reviews Clinical Oncology, 2023
- Population-Based Newborn Screening for Germline TP53 Variants: Clinical Benefits, Cost-Effectiveness, and Value of Further ResearchJNCI: Journal of the National Cancer Institute, 2022
- Genomes for Kids: The Scope of Pathogenic Mutations in Pediatric Cancer Revealed by Comprehensive DNA and RNA SequencingCancer Discovery, 2021
- Global childhood cancer survival estimates and priority-setting: a simulation-based analysisThe Lancet Oncology, 2019
- Estimating the total incidence of global childhood cancer: a simulation-based analysisThe Lancet Oncology, 2019
- Clinical, Radiologic, Pathologic, and Molecular Characteristics of Long-Term Survivors of Diffuse Intrinsic Pontine Glioma (DIPG): A Collaborative Report From the International and European Society for Pediatric Oncology DIPG RegistriesJournal of Clinical Oncology, 2018
- Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing LossNew England Journal of Medicine, 2018